Press Release

The new drug substance BTZ043 is being tested on patients for the first time in a Phase II study performed by the PanACEA consortium. The trial is carried out in Cape Town, South Africa at TASK Applied Science Clinical Research Centre and the University of Cape Town Lung Institute (UCTLI).

The study is funded by the German Federal Ministry of Education and Research (BMBF) and the European and Developing Countries Clinical Trials Partnership (EDCTP).

BTZ043 was discovered at the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (Leibniz-HKI) in Jena. Since 2014, the new chemical entity has been developed in a consortium of scientists from the Leibniz-HKI and the Tropical In-stitute at the Hospital of the LMU Munich within the framework of the German Center for Infection Research (DZIF).

“Following the promising results of the Phase I study in Germany, we see a great chance that the good tolerability of BTZ043 will be confirmed in the treatment of tuberculosis patients. We are confident that we will also see good results in the first efficacy data.” Says Professor Michael Hoelscher, who is leading the Phase II study. If BTZ043 proves to be safe and effective in the current study, this would be a major step in the development of a new drug.

More information:
LMU press release
Clinical trial registration
About BTZ043